The effectiveness of RAS/MAPK inhibitors in treating metastatic KRAS-mutant non–small cell lung cancer (NSCLC) is often hindered by the development of resistance driven by disrupted negative feedback mechanisms led by phosphatases like PP2A. PP2A is frequently suppressed in lung cancer...

U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07252739) titled 'KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C...

Changes in the KRAS gene can affect how lung cancer develops, as well as its treatment and survival rates. Learn more here Key takeawaysKRAS mutations lead to excessive cell growth due to alterations in the KRAS gene. They are present...

IntroductionKi-ras2 (KRAS) mutation is a common driver of lung cancer, and KRAS-mutated tumors are relatively resistant to radiotherapy. Previously, we demon 1 Introduction Ki-ras2 (KRAS) mutations serve as driver genes in non-small cell lung cancer (NSCLC), with approximately 27% incidence...